Tysabri Return To Market For First-Line Use In Relapsed MS Supported By Slim Majority
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee unanimously agrees that Biogen Idec's natalizumab should be reintroduced for at least some multiple sclerosis patients.